Use of the Polymerase Chain Reaction to Detect Viral Contamination of Clotting Factor Concentrates

  • M. Makris
Conference paper


Although the introduction of viral inactivation methods has dramatically reduced the capacity of clotting factors to transmit viral infections, rare transmissions continue to occur. The polymerase chain reaction (PGR) is an extremely sensitive technique that can detect minute amounts of viral genomic material in these products. It has been used to show contamination of factor VIII concentrates with hepatitis C (HCV), human immunodeficiency virus (HIV), hepatitis A (HAV) and parvovirus B19. In the case of HCV and HAV it has been shown that detection of viral product in the concentrate is associated with transmission of infection to the recipient.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson MJ, Pattison JR (1987) Parvoviruses. In: Weatherall DJ, Ledingham JGG, Warrell DA (eds) Oxford textbook of medicine, 2nd edn. Oxford Medical, pp 5.162–5.164Google Scholar
  2. Barbara JAJ, Garson JA (1993) Polymerase chain reaction and transfusion microbiology. Vox Sang 64: 73–81PubMedCrossRefGoogle Scholar
  3. Brackmann HH, Egli H (1988) Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate. Lancet II: 967CrossRefGoogle Scholar
  4. Carman WF, Zanetti AR, Karayiannis P et al (1990) Vaccine-induced escape mutant of hepatitis B virus. Lancet 336: 325–329PubMedCrossRefGoogle Scholar
  5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of cDNA clone from a blood borne non-A, non-B viral hepatitis genome. Science 244: 359–362PubMedCrossRefGoogle Scholar
  6. Fletcher ML, Trowell JM, Craske J, Pavier K, Rizza CR (1983) Non-A, non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J 287: 1754CrossRefGoogle Scholar
  7. Garson JA, Tedder RS, Briggs M et al (1990a) Detection of hepatitis C viral sequences in blood donation by “nested” polymerase chain reaction and prediction of infectivity. Lancet 335: 1419PubMedCrossRefGoogle Scholar
  8. Garson JA, Ring C, Tuke P, Tedder RS (1990b) Enhanced detection by PCR of hepatitis C virus RNA. Lancet 336: 1022PubMedCrossRefGoogle Scholar
  9. Gerritzen A, Schneweis KE, Scholt B et al (1992) Acute hepatitis C in haemophiliacs due to “virus-inactivated” clotting factor concentrates. Thromb Haemostas 68: 781Google Scholar
  10. Kernoff PBA, Lee CA, Karayiannis P, Thomas HC (1985) High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates; effect of prophylactic immune serum globulin. Br Haematol 80: 469CrossRefGoogle Scholar
  11. Kleim JP, Bailly E, Schneweis KE et al (1990) Acute HIV-1 infection in patients with haemophilia B treated with beta-propiolactone-UV-inactivated clotting factor. Thromb Haemostas 64: 336–337Google Scholar
  12. Kwok S, Higuchi R (1989) Avoiding false positives with PCR. Nature 339: 237–328PubMedCrossRefGoogle Scholar
  13. Lefrere JJ, Mariotti M, Thauvin M (1994) B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 343: 211–212PubMedCrossRefGoogle Scholar
  14. Makris M, Garson JA, Ring CJA, Tuke PW, Tedder RS, Preston FE (1993) Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 81: 1898–1902PubMedGoogle Scholar
  15. Mannucci PM (1992) Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 339: 819PubMedCrossRefGoogle Scholar
  16. Mannucci PM, Colombo M (1989) Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemostas 61: 532–534Google Scholar
  17. Mannucci PM, Gdovin S, Gringeri A et al (1994) Transmission of hepatitis A to patients with haemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 120: 1–7PubMedGoogle Scholar
  18. Naides SJ, Howard EJ, Swack NS, True CA, Stapleton JT (1993) Parvovirus B19 infection in human immunodeficiency virus type-1 infected persons failing or intolerant to zidovudine therapy. J Infect Dis 168: 101–105PubMedCrossRefGoogle Scholar
  19. Rizza CR, Spooner RJD (1983) Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976–1980: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J 286: 929–933CrossRefGoogle Scholar
  20. Semple MG, Loveday C, Preston FE, Tedder RS (1991) Detection of HIV-1 RNA in factor FVIII concentrate. AIDS 5: 597–598PubMedCrossRefGoogle Scholar
  21. Simmonds P, Zhang LQ, Watson HG et al (1990) Hepatitis C quantification and sequencing in blood products, haemophiliacs and drug users. Lancet 336: 1469–1472PubMedCrossRefGoogle Scholar
  22. Tedder RS, Briggs M, Ring C, Tuke PW, Jones P, Savidge GF, Rodgers B, Garson JA (1991) Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 79: 512PubMedCrossRefGoogle Scholar
  23. Watson HG, Ludlam CA, Rebus S, Zhang LQ, Peutherer JF, Simmonds P (1992) Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 80: 514–518PubMedCrossRefGoogle Scholar
  24. Zakrzewska K, Azzi A, Patou G, Morfini M, Rafanelli D, Pattison JR (1992) Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br J Haematol 81: 407–412PubMedCrossRefGoogle Scholar
  25. Zhang LQ, Simmonds P, Ludlam CA, Leigh Brown AJ (1991) Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS 5: 675–681PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • M. Makris

There are no affiliations available

Personalised recommendations